Publication at First Faculty of Medicine |
2020
Abstract
Ocrelizumab (Ocrevus [Roche, Basel, Switzerland]) is the first and so far registered product for the treatment of patients with both relapsing MS (RRS) and primary progressive MS (PPRS). This recombinant humanized monoclonal antibody selectively targets B-cells expressing the CD20 surface antigen.
The article evaluates the effect of ocrelizumab in slowing thalamic atrophy in patients with RRS and PPRS